Unicycive Therapeutics (UNCY) Share-based Compensation (2020 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Share-based Compensation came in at $754000.0 in Q1 2026, up 33.93% YoY from $563000.0 in Q1 2025, and down 3.08% on a QoQ basis from $778000.0 in Q4 2025.
Unicycive Therapeutics (UNCY) Share-based Compensation (2020 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 7 years of Share-based Compensation data on file, last reported at $754000.0 in Q1 2026.
- Quarterly Share-based Compensation rose 33.93% year-over-year to $754000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 18.44% YoY) and the FY2025 annual result came in at $5.6 million, up 1.82% from the prior year.
- Share-based Compensation slipped to $754000.0 in Q1 2026, from $778000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $929000.0 in Q3 2023 to a low of $144000.0 in Q1 2023.
- A 5-year average of $503470.6 and a median of $563000.0 in 2025 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation tumbled 51.02% — and 2024, when it jumped 345.14%.
- Tracing UNCY's Share-based Compensation over 5 years: stood at $197000.0 in 2022, then soared by 179.19% to $550000.0 in 2023, then rose by 5.82% to $582000.0 in 2024, then soared by 33.68% to $778000.0 in 2025, then fell by 3.08% to $754000.0 in 2026.
- The last three Share-based Compensation figures came in at $754000.0 (Q1 2026), $778000.0 (Q4 2025), and $729000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | - |
| 10 | Unicycive Therapeutics | 151.14 Mn | 151.14 Mn | - | 2.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.88 Mn |
| Jun 30, 2026 | 2.88 Mn |
| Mar 31, 2026 | 754,000.00 |
| Mar 31, 2026 | 754,000.00 |
| Dec 31, 2025 | 778,000.00 |
| Dec 31, 2025 | 778,000.00 |
| Sep 30, 2025 | 729,000.00 |
| Sep 30, 2025 | 729,000.00 |
| Jun 30, 2025 | 571,000.00 |
| Jun 30, 2025 | 571,000.00 |
| Mar 31, 2025 | 563,000.00 |
| Mar 31, 2025 | 563,000.00 |
| Dec 31, 2024 | 582,000.00 |
| Dec 31, 2024 | 582,000.00 |
| Sep 30, 2024 | 605,000.00 |
| Sep 30, 2024 | 605,000.00 |
| Jun 30, 2024 | 641,000.00 |
| Jun 30, 2024 | 641,000.00 |
| Mar 31, 2024 | 522,000.00 |
| Mar 31, 2024 | 522,000.00 |